KR101974645B1 - A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same - Google Patents

A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same Download PDF

Info

Publication number
KR101974645B1
KR101974645B1 KR1020160163662A KR20160163662A KR101974645B1 KR 101974645 B1 KR101974645 B1 KR 101974645B1 KR 1020160163662 A KR1020160163662 A KR 1020160163662A KR 20160163662 A KR20160163662 A KR 20160163662A KR 101974645 B1 KR101974645 B1 KR 101974645B1
Authority
KR
South Korea
Prior art keywords
film
glucose
hemoglobin
membrane
phosphate dehydrogenase
Prior art date
Application number
KR1020160163662A
Other languages
Korean (ko)
Other versions
KR20180063646A (en
Inventor
이효근
원유덕
송병학
김병수
이세인
Original Assignee
에스디 바이오센서 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스디 바이오센서 주식회사 filed Critical 에스디 바이오센서 주식회사
Priority to KR1020160163662A priority Critical patent/KR101974645B1/en
Priority to BR112019010868A priority patent/BR112019010868A2/en
Priority to PCT/KR2016/014426 priority patent/WO2018101525A1/en
Publication of KR20180063646A publication Critical patent/KR20180063646A/en
Application granted granted Critical
Publication of KR101974645B1 publication Critical patent/KR101974645B1/en

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/726—Devices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01049—Glucose-6-phosphate dehydrogenase (1.1.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Abstract

The present invention relates to a porous film; A solution-treated membrane containing glucose-6-phosphate, immobilized on top of the porous film; And simultaneous measurement of total-hemoglobin and glucose-6-phosphate dehydrogenase, comprising a mesh attached to the membrane with a structure that includes all of the membrane and a portion of the membrane protruding from the membrane at a size equal to or greater than the membrane. And a method for manufacturing the strip and its application. The strips of the present invention simultaneously and simultaneously measure whole-hemoglobin and glucose-6-phosphate dehydrogenase on the same strip, providing readings through accurate and accurate quantification, thereby providing an advantage of quickly and accurately measuring the concentration of G6PD corrected to total hemoglobin concentration .

Description

FIELD OF THE INVENTION [0001] The present invention relates to a strip for simultaneous measurement of total-hemoglobin and glucose-6-phosphate dehydrogenase, a method for producing the same, }

The present invention relates to a porous film comprising a solution-treated film containing glucose-6-phosphate immobilized on the top of the porous film, and a film-forming solution containing the whole of the film on the top of the film, Hemoglobin and a glucose-6-phosphate dehydrogenase simultaneous measurement strip including a mesh attached with a structure in which a part of the membrane protrudes from the membrane in a large size, a method for producing the same, and an application thereof.

Glucose-6-phosphate dehydrogenase (hereinafter referred to as 'G6PD') deficiency is a worldwide disease with a prevalence of 4.9%. It is estimated to have about 400 million patients and is the most common enzyme deficiency. G6PD deficiency is an X chromosomal genetic disorder and a variety of biochemical enzyme abnormalities and clinical symptoms arise due to genetic defects caused by mutations in the G6PD gene. The most common symptoms are neonatal jaundice and acute hemolytic anemia. Most acute hemolytic anemia is caused by external factors. In 1956, it was reported that G6PD activity was decreased in hemolytic patients after taking the malaria drug Primaquine. It has been found that most G6PD deficiency patients are asymptomatic and have a high likelihood of causing neonatal hemolysis or causing hemolytic anemia due to certain medications or some infections.

Most G6PD deficiency patients are often asymptomatic over a lifetime, often without knowing whether they are patients. Acute hemolysis is caused by oxidative stress on red blood cells when ingested with certain drugs, infections or beans. Oxidative stress oxidizes glutathione in red blood cells (Reduced glutathione, GSH -> Oxidative glutathione, GSSG). G6PD deficient red blood cells have a limitation in reducing glutathione, so that the remaining GSH is rapidly depleted, Irreversible damage to the red blood cells is destroyed.

The point-of-care test (POCT) is a direct examination from the patient's place. It is the formerly called examination of the patient side, the examination room, the bed examination, the auxiliary examination performed outside the hospital do.

In other words, the clinical pathology test is not carried out in the central laboratory of the medical institution but is performed by the patient himself or herself, at home, at the workplace, etc., or by the doctor, nurse or clinician in the ward, emergency room, surgical field or intensive care unit.

Particularly noteworthy is that the sample can be used directly at an individual clinic rather than sent to an inspection center. The main items of the field test are blood glucose analysis performed by the patient, the caregiver and the healthcare personnel, the blood gas analysis performed by the healthcare personnel, the cardiac enzyme test, the general blood test (CBC) There are routine chemistry tests, urine tests, immunoenzymes such as HBsAg / Ab, electrolyte tests, some microbiological tests, occult blood tests, lactic acid tests and so on.

The tests that can be performed by the field test are almost all items that can be inspected by the central laboratory today. In the past, field inspections which have been questioned about the reliability of inspections and which had to be verified as the inspectors of central inspections have been developed rapidly, so that the problem of reliability has been solved.

By inventing a POC product that enables field testing of G6PD through such a technology, it is demanding that it can be inspected at any time and place when necessary.

[Prior Patent Literature]

Korean Patent Publication No. 10-2014-0072023

The present invention has been made in view of the above needs, and it is an object of the present invention to provide a product capable of on-site inspection of G6PD.

It is an object of the present invention to provide a novel on-site inspection method of G6PD.

In order to attain the above object, the present invention provides a method for producing a porous membrane, which comprises mixing a solution prepared by mixing a solution containing glucose-6-phosphate with a surfactant and a polymer in a membrane, drying the membrane, , A mesh for uniformly spreading a blood sample on the top of the membrane, the membrane having a size equal to or greater than the membrane, a portion of the membrane protruding from the membrane, The present invention provides a method for producing a strip for simultaneous measurement of all-hemoglobin and glucose-6-phosphate dehydrogenase.

In one embodiment of the invention, the solution is selected from the group consisting of? -Nicotin amide adenine diclcreotide (NADP), tetrazolium, and 5-bromo-4-chloro-3- It is preferred, but not limited, to include one or more selected materials.

In another embodiment of the present invention, the membrane is preferably, but not limited to, selected from Poly sulfone, Poly ether sulfone, Nylon, and Nitro Cellulose .

In another embodiment of the present invention, the porous film is preferably made of polyethylene phthalate, but is not limited thereto.

In another embodiment of the present invention, the mesh is preferably made of a hydrophilic polyester material, but is not limited thereto.

The present invention also relates to a method for preparing a porous membrane, which comprises: a membrane pretreated with a solution containing glucose-6-phosphate immobilized on top of the porous membrane; Hemoglobin and glucose-6-phosphate dehydrogenase, comprising a mesh attached with a structure having the same size as the membrane or larger than the membrane and partially protruding from the membrane, Provide a strip for use.

The present invention also relates to a method for fabricating a strip, comprising: applying a sample to a mesh portion of the strip of the present invention; And

6-phosphate and glucose-6-phosphate dehydrogenase react with each other at the membrane site to cause a color reaction, thereby exhibiting a specific color, and coloring the resultant color to be quantified through light emission of the measuring instrument and light reception Hemoglobin and glucose-6-phosphate dehydrogenase from a sample containing the enzyme.

In the above, the 'quantification' principle is that hemoglobin (Hb), when the sample is mixed with Lysis Buffer before the G6PD color reaction, changes into HbO2 state by binding with oxygen, and the emission and the light immediately after addition to the sample film are quantified And the% Ref value of the difference between G6PD and 300Sec based on the% Ref value at the time of hemoglobin measurement is quantified based on the difference.

In one embodiment of the present invention, the sample is preferably whole blood, but is not limited thereto.

Hereinafter, the present invention will be described.

The present invention is based on the observation that the strip measurement structure is changed to G6PD Enzyme Activity reaction at the lower reaction membrane by flow through the sample, and then the Dye reaction by the oxidation-reduction reaction occurs to purple, The present invention relates to an analytical method that can be measured through a measuring instrument.

Internationally, it is important to develop products that can measure simultaneously with total hemoglobin, not just G6PD. For example, Carestart G6PD electrochemicals can not measure total hemoglobin simultaneously, Is a measure of U / dL only. These existing G6PD measurement products currently have the disadvantage that they can not quantify the G6PD IU / g Hb, which is an important unit measure for G6PD deficiency testing internationally.

The present invention can quantify IU / g Hb which is most important for G6PD deficiency measurement at present and does not provide an accurate result according to the total-hemoglobin concentration. In addition, it has developed a product that can measure anytime and anywhere advantage of POCT.

The strip of the present invention simultaneously measures both Total-Hemoglobin and Glucose-6-phosphate dehydrogenase within 5 minutes, eliminating any interference due to the total hemoglobin concentration by providing an easy and simple procedure and accurate quantification of the readings. The present invention provides advantages that include simple and straightforward procedures through quick and accurate quantification.

Figure 1 is a precision table. Total-hemoglobin and G6PD measurements were carried out using the strip of the present invention and G6PD measurement was performed and the results were shown to be sufficient to quantify. After preparing the experiment as in Example-1, the coefficient of variation CV% and the standard deviation STDEV As a result of measuring the reproducibility performance of a quantitative product commonly used in a measurement system, the result of measurement as shown in FIG. 1 is that of a normal (6 U / g Hb) or more and an intermediate & deficiency (less than 6 U / g Hb) Good results.
2 is a graph of linearity. The G6PD concentration was measured by the present invention as shown in Table 2. The instrument was named Hitachi Automatic Chemical Analyzer. The G6PD deficiency concentration and the normal concentration sample were measured in 9 steps As a result of measurement experiment made by making it Contrived.
Figure 3 shows the appearance of the device of the invention.
FIG. 4 shows a graph of the parameter measurement algorithm, and G6PD of the present invention shows a difference rate of change of 1 to 300 seconds according to the concentration as shown in the graph. The hemoglobin (Hb) When Hb is added to the HbO2 state, the light emission and the light emission after the addition to the sample film are quantified by the data. G6PD is the% Ref of the difference between 300Sec based on the% Ref value at the time of hemoglobin measurement Values are quantified based on differences.
5 is a comparison chart of the present invention and the Symmetric comparison Precision performance. Glucose-6-phosphate 5 mM, β-Nicotinamide adenine dinucleotide 5 mM (NADP) and Tetrazolium 0.5 mM BCIP 0.4 mM (Or BCPIP) were mixed with the appropriate TX-100 and polyvinylpyrrolidone in a Tris 50 mM pH 8.0 solution for G6PD measurement The prepared solution was treated with symmetric membrane, Nylon membrane and asymmetric membrane, poly ether sulfone membrane, and dried. This test was repeated 5 times using a sample of normal G6PD concentration and the performance of the asymmetric membrane was excellent as shown in FIG.
FIG. 6 is a diagram illustrating the measurement structure of the present invention in comparison with a conventional product. FIG. 6 is a diagram illustrating the structure of a product of the lateral flow method, which is a conventional G6PD RDT technology, and the strip structure of the present invention. It has the advantages of improved productivity and excellent performance.
FIG. 7 is a performance comparison chart according to the strip structure. As a result of the performance comparison, the flow through measurement method according to the present invention has a better performance than the conventional G6PD RDT method. It is confirmed that this is a big improvement in Precision performance which is important for quantitative measurement. The G6PD solution was treated on the membrane and dried. Later flow method, which is a conventional method for comparative evaluation, was made to measure side by side with a pad made of polyester material and a pad made of glass fiber. Membrane was made by attaching a mesh so that the entire pad was covered on the dried pad. The strips of these two structures were subjected to five repeated precision tests using a sample of normal G6PD concentration and the measurement performance of the flow through structure was excellent as shown in FIG.

The present invention will now be described in more detail by way of non-limiting examples. The following examples are intended to illustrate the present invention and the scope of the present invention is not to be construed as being limited by the following examples.

Example  1: Production and measurement principle of the strip of the present invention

For the G6PD assay, 5 mM Tris-6-phosphate, 5 mM N-acetylglucosamine adenine dinucleotide (NADP) and Tetrazolium 0.5 mM BCIP 0.4 mM (Or BCPIP) were added to a solution of Tris 50 mM pH 8.0 with appropriate detergent and polymer Polyvinylpyrrolidone) is mixed and dried in a membrane made of Poly sulfone, Poly ether sulfone, Nylon, Nitro Cellulose, etc.

After the sample is cut into the appropriate size (5mm), the sample is fixed on the cross-linked adhesive porous film of PET, and the mesh (15mm), which is a material for spreading the blood sample, is fixed on the top. Cut the immobilized film card into the appropriate size (5mm) and place it on the device, which is made of poly carbonate or ABS material, and prepare it for use.

Lysis buffer preparation for G6PD was performed by combining 0.5% of TX-100, polymer, and protein in a Tris 50 mM pH 8.0 solution.

The G6PD dedicated measuring instrument is able to measure Total-Hemoglobin & G6PD by changing the% reflectance on the principle of emitting and receiving 525nm wavelength. After inserting the prepared device strip into the measuring device, the whole blood specimen is diluted 21X in the lysis buffer. After the dilution is completed, if the sample is spotted on the strip, the measurement starts when the blood is detected and the measurement time is 5 minutes. When the measurement is completed, the displayed values can be checked at the same time for two values of Total Hemoglobin g / dL and G6PD U / g Hb.

When blood is detected in the device strip, Glucose-6-phosphate reacts with the G6PD enzyme and the NADP reagent is reduced to NADPH. The NADPH-reduced reagent is again oxidized to NAPD. This redox reaction causes the NADPH Appears as a purple or blue formazan color with reduced reduction of the tetrazolium salt. The NADP and NADPH redox reactions are more activated by the higher concentration of G6PD in the blood, and the resulting color is quantitated by measuring the light emission and receiving light.

The precision and linearity performance test for evaluating the G6PD measuring apparatus manufactured according to the above embodiment was carried out, and the results are shown in FIG. Through this technology, patients with G6PD deficiency, a global hereditary disease, developed a technique to use the easily measurable G6PD level as a quantified product, such as Primaquine, which is a treatment for malaria, before the drug prescription, so that the damage caused by acute hemolysis .

Example 2: Bonn  Invention measuring instrument

The outer appearance of the measuring device of the present invention is made in a compact size which can be held by one hand, and the measurement operating temperature is dynamic from 18C to 40C. As a result, it is used as a product suitable for measurement in various places, not limited to the laboratory. After the measurement is completed, the units for the displayed items are quantified by displaying the values of Total-Hemoglobin (g / dL) and G6PD (U / g Hb).

Experimental Example  One. G6PD  & Total Hemoglobin simultaneous measurement method (5 ~ 30 sec Total- Hemoglobin measurement , 300 seconds G6PD measurement )

Glucose-6-phosphate 5 mM, β-Nicotinamide adenine dinucleotide 5 mM (NADP) and Tetrazolium 0.5 mM BCIP 0.4 mM (Or BCPIP) were mixed with the appropriate TX-100 and polyvinylpyrrolidone in a Tris 50 mM pH 8.0 solution for G6PD measurement The prepared solution was treated with symmetric membrane, Nylon membrane and asymmetric membrane, poly ether sulfone membrane, and dried. G6PD is divided into normal and defective samples according to the concentration and then the measurement is progressed. By applying the linear function and the quadratic function to the difference of the reflectance (% Ref), the numerical value is changed to the actual concentration. The measurement principle is hemoglobin (Hb) When G6PD is mixed with Lysis Buffer, Hb is converted to HbO2 state by mixing with Lysis Buffer, and the light emission and light reception after addition to the sample film are quantified by the data. G6PD is the% Ref value at the time of hemoglobin measurement The% Ref value of the difference between 300Sec as a criterion is quantified based on the difference

Hemoglobin is converted to HBO2 by binding to oxygen when the sample is mixed with Lysis Buffer before the G6PD color reaction, and the light emission and the light received immediately after addition to the sample film are quantified by the data. G6PD is the% Ref value at the time of hemoglobin measurement , The% Ref value of the difference between the changes of 300 seconds is quantified based on the difference

Experimental Example 2: Bonn  Comparison of Asymmetric Structure Membranes and Porous Symmetric Membranes of the Invention

G6PD is a composition for measuring G6PD, which is composed of 5 mM of glucose-6-phosphate, 5 mM of β-nicotinamide adenine dinucleotide, and a solution of Tris 50 mM pH 8.0 in order to compare the performance of the membrane with asymmetric polymer structure to the porous symmetric membrane (NADP), Tetrazolium 0.5 mM BCIP 0.4 mM (Or BCPIP) were mixed with the appropriate detergent and polymer. The symmetric membrane was a membrane of Nitro Cellulose, the Asymmetric membrane used in the present invention was a membrane of poly sulfone And then dried at 40 ° C for 20 minutes. Measurements were carried out at room temperature.

The coefficient of variation CV% and the standard deviation STDEV are the units that represent the reproducibility of the quantitative products commonly used in quantitative measurement systems. The measured results are shown as Normal (6U / g Hb), Intermediate & Deficiency (6U / g Hb). Therefore, it shows excellent reproducibility and accuracy enough to quantify against the conventional RDT G6PD.

In addition, the G6PD solution was treated on the membrane and dried. In the lateral flow through method for comparative evaluation, a polyester sample pad and a glass fiber moisture absorbing pad were stacked on each other, Membrane was made by attaching a mesh so that the entire pad was covered on the dried pad. The strips of these two structures were subjected to five repeated precision tests using a sample of normal G6PD concentration and the measurement performance of the flow through structure was shown as shown in FIG.

Claims (11)

A single-sided adhesive film having two holes for measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, respectively;
A film pretreated with a solution containing glucose-6-phosphate in which the entirety of two holes are formed at the upper end of the hole of the film and a part of both ends of the film are immobilized on the single-
A mesh attached to the single-sided adhesive portion of the film in such a structure that the whole of the film is on top of the film and a portion of the film protrudes from the film to a length longer than the length of the film;
Lt; / RTI >
Wherein the membrane is polysulfone or polyether sulfone, which is an asymmetric membrane, and simultaneously measures quantitatively the total-hemoglobin and glucose-6-phosphate dehydrogenase by the colorimetric method. delete delete [3] The strip according to claim 1, wherein the film is a polyethylene phthalate material. 3. The strip according to claim 1, wherein the film is a polyethylene phthalate material, and the total-hemoglobin and glucose-6-phosphate dehydrogenase are simultaneously quantitatively measured. The strip according to claim 1, wherein the mesh is a polyester material having hydrophilic properties. A strip for quantitatively measuring all-hemoglobin and glucose-6-phosphate dehydrogenase simultaneously. delete delete delete delete Applying a sample to a mesh portion of the strip of claim 1;
6-phosphate and glucose-6-phosphate dehydrogenase react with each other at the membrane site to cause a color reaction, thereby exhibiting a specific color, and coloring the resultant color to be quantified through light emission of the measuring instrument and light reception doing
A method for simultaneous quantitative measurement of total-hemoglobin and glucose-6-phosphate dehydrogenase from the same strip by a colorimetric method.
delete
KR1020160163662A 2016-12-02 2016-12-02 A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same KR101974645B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020160163662A KR101974645B1 (en) 2016-12-02 2016-12-02 A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same
BR112019010868A BR112019010868A2 (en) 2016-12-02 2016-12-09 strip for simultaneous measurement of total hemoglobin and glucose-6-phosphate dehydrogenase, method of manufacture thereof, and application thereof
PCT/KR2016/014426 WO2018101525A1 (en) 2016-12-02 2016-12-09 Strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, manufacturing method therefor, and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160163662A KR101974645B1 (en) 2016-12-02 2016-12-02 A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same

Publications (2)

Publication Number Publication Date
KR20180063646A KR20180063646A (en) 2018-06-12
KR101974645B1 true KR101974645B1 (en) 2019-05-02

Family

ID=62242797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160163662A KR101974645B1 (en) 2016-12-02 2016-12-02 A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same

Country Status (3)

Country Link
KR (1) KR101974645B1 (en)
BR (1) BR112019010868A2 (en)
WO (1) WO2018101525A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162397A (en) * 1998-08-13 2000-12-19 Lifescan, Inc. Visual blood glucose test strip
US5902731A (en) * 1998-09-28 1999-05-11 Lifescan, Inc. Diagnostics based on tetrazolium compounds
US6420128B1 (en) * 2000-09-12 2002-07-16 Lifescan, Inc. Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same
US7425302B2 (en) * 2003-02-24 2008-09-16 Binax, Inc. Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays
ATE479096T1 (en) * 2004-07-29 2010-09-15 Relia Diagnostic Systems Llc CROSS-FLOW SYSTEM AND ASSAY
KR101203385B1 (en) * 2009-06-04 2012-11-21 주식회사 인포피아 Test strip improved spreadability of plasma or serum
KR101177353B1 (en) * 2010-10-08 2012-11-15 주식회사 메디센서 Diagnostic Apparatus and Diagnostic Method Using the Same
CN108107211B (en) * 2011-07-22 2020-06-09 阿赛斯生物股份有限公司 Single spacer for improved lateral flow assay

Also Published As

Publication number Publication date
BR112019010868A2 (en) 2019-10-01
WO2018101525A1 (en) 2018-06-07
KR20180063646A (en) 2018-06-12

Similar Documents

Publication Publication Date Title
CN105021596B (en) Multilayer film dry chemical detection strip based on concentration gradient
JP3698696B2 (en) Biological sample preparation method, biological sample quantification method, and biological sample storage container
Léguillier et al. Lactate POCT in mobile intensive care units for septic patients? A comparison of capillary blood method versus venous blood and plasma-based reference methods
Lima-Oliveira et al. Different manufacturers of syringes: a new source of variability in blood gas, acid–base balance and related laboratory test?
KR101751205B1 (en) A single-pad strip for an improved lateral flow assay and a test device using the same
JP5379809B2 (en) Automatic method and apparatus for detecting erroneous sample collection in clinical analysis
Wiener Whole blood glucose: what are we actually measuring?
Cao et al. Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system
CN104937403A (en) Device including biosensor and holder
EP2882341B1 (en) Kits and methods for determining physiologic level(s) and/or range(s) of hemoglobin and/or disease state
JP2023078412A (en) In-vitro hemolysis detection and correction of at least one blood parameter in whole blood sample
Kristensen et al. Self-monitoring of blood glucose with a focus on analytical quality: an overview
Fliervoet et al. Comparison of capillary and venous blood sampling for routine coagulation assays
Temel et al. Determination of dynamic thiol/disulphide homeostasis in children with tetralogy of Fallot and ventricular septal defect
KR101974645B1 (en) A strip for simultaneously measuring total-hemoglobin and glucose-6-phosphate dehydrogenase, a preparing method thereof, and a use of the same
McKinley ISFET and fiber optic sensor technologies: In vivo experience for critical care monitoring
Misiano et al. Current and future directions in the technology relating to bedside testing of critically III patients
Nanji et al. Near-patient testing: Quality of laboratory test results obtained by non-technical personnel in a decentralized setting
WO2007034284A1 (en) Method to measure the total anti-oxidant capacity of a biological sample and kit thereof
Jamaluddin et al. Variability of point-of-care testing blood glucometers versus the laboratory reference method in a tertiary teaching hospital
Selleri et al. Point-of-care blood gases, electrolytes, chemistries, hemoglobin, and hematocrit measurement in venous samples from pet rabbits
CN107271500A (en) A kind of uric acid biochemical analysis dry plate and preparation method thereof and reagent disc
Santos et al. Evaluation of three human-use glucometers for blood glucose measurement in dogs
Sardesai et al. The determination of methanol in biological fluids
CN109632774A (en) Dry chemical detection sensor and preparation method thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant